Allot Announces Launch of Underwritten Public Offering of Ordinary Shares
The Company expects to use the net proceeds of the public offering to repay $31.41 million of principal outstanding under the senior unsecured convertible promissory note with a face value of $40.0 million issued by the Company to its largest shareholder, Lynrock Lake Master Fund LP ('Lynrock'), on February 18, 2022 (as amended, the 'Lynrock Note'), and the balance for general corporate purposes.
In connection with the offering, Lynrock has agreed to convert the remaining $8.59 million of principal outstanding under the Lynrock Note into ordinary shares. Lynrock will enter into a customary lock up agreement with the underwriters with respect to its ordinary shares, including those to be issued upon conversion of the Lynrock Note, for a period of 75 days following the date of the final prospectus supplement. The Company will have no outstanding indebtedness for borrowed money following the repayment and conversion of the Lynrock Note.
In addition, the Company expects to grant the underwriters of the public offering a 30-day option to purchase from the Company up to an additional 15% of the ordinary shares sold in the public offering at the public offering price, less underwriting discounts and commissions.
TD Cowen and William Blair are acting as the joint book-running managers, and Needham & Company is acting as lead manager, with respect to the public offering of the ordinary shares.
The public offering is being made pursuant to an effective shelf registration statement on Form F-3 previously filed by the Company with the U.S. Securities and Exchange Commission (the 'SEC') and declared effective on April 3, 2025. The public offering of ordinary shares is being made only by means of a prospectus supplement and accompanying prospectus. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. Copies of the prospectus supplement and accompanying prospectus relating to the public offering may be obtained free of charge at the SEC's website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus may be obtained from: TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by email at TD.ECM_Prospectus@tdsecurities.com or by telephone at (855) 495-9846; and William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described above, nor shall there be any offer, solicitation or sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, solicitation or sale of such securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Allot
Allot Ltd. (Nasdaq: ALLT, TASE: ALLT) is a leading global provider of innovative network intelligence and security solutions for service providers and enterprises worldwide.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the size and timing of the public offering, the granting of an option by the Company to the underwriters to purchase additional ordinary shares from the Company, the proposed use of proceeds of the public offering, and the repayment and conversion of the Lynrock Note. These statements are not historical facts but rather are based on Allot's current expectations and projections regarding its business, operations and other factors relating thereto. Words such as 'expect,' 'intend,' 'believe,' 'may,' 'will,' 'should,' and other words and terms of similar meaning (including their negative counterparts or other various or comparable terminology) are used to identify these forward-looking statements. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those set forth in the 'Risk Factors' section of the registration statement and the prospectus supplement for the public offering and the Company's other filings with the SEC. Any such forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and speak only as of the date of this press release. Allot undertakes no duty to update any forward-looking statements made herein.
CONTACT: Seth Greenberg Allot +972 54 922 2294 sgreenberg@allot.com Ehud Helft / Kenny Green Allot Investor Relations +1-212-378-8040 Allot@ekgir.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Amazon.com, Inc. (AMZN): Jim Cramer Maintains It Needs To Buy NVIDIA
We recently published . Inc. (NASDAQ:AMZN) is one of the stocks Jim Cramer recently discussed. Inc. (NASDAQ:AMZN) is struggling on the stock market lately as investors are worried about the growth prospects of its cloud computing division. The shares have gained a mere 1.4% over the past month, after they fell by 9.6% after the firm's second quarter earnings were accompanied by weak AWS growth. Cramer continues to maintain that Inc. (NASDAQ:AMZN) is struggling because it is focusing on its in-house AI chips instead of NVIDIA's AI GPUs: 'Think about what happened to Amazon, when they decided to go away from using all the NVIDIA that was possible. . . Copyright: veghsandor / 123RF Stock Photo Here are his previous thoughts about Inc. (NASDAQ:AMZN): 'We're in the era, this is what happens, The two big overhangs in this market had been Apple waiting for the sword of Damocles and Amazon, trading down because Amazon Web Services is viewed as a share donor. Both of those seem to have been forgotten. David, the forgotten negatives there has been replaced by we're dumping the big tariffs for now.' While we acknowledge the potential of AMZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
27 minutes ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Cerence Inc. (CRNC) Might Be A Hidden Gem, Says Jim Cramer
We recently published . Cerence Inc. (NASDAQ:CRNC) is one of the stocks Jim Cramer recently discussed. Cerence Inc. (NASDAQ:CRNC) is a software company that caters to the needs of the transportation industry. Its shares have gained 60% year-to-date and gained an unbelievable 45% in August. Cerence Inc. (NASDAQ:CRNC) is benefiting from the AI wave through having landed major deals, such as a partnership with Mercedes-Benz. Cramer discussed the firm in the context of it being an outlier that could be interesting in the AI era: 'I'm doing a piece about Cerence tonight. People are going to want to find out what I'm saying there. There's a lot of technology away from these big companies that is better than the big companies.' Copyright: audioundwerbung / 123RF Stock Photo Here are Cramer's previous thoughts about Cerence Inc. (NASDAQ:CRNC): 'I like Cerence, and I also happen to like Brian Krzanich, the CEO. I am partial. They make money. I think you've got a winner. I was actually trying to figure out whether I could justify doing a piece on it because it's not that expensive. Cerence is a winner, and Brian's always welcome on the show, as we know.' While we acknowledge the potential of CRNC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data